View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Clinical Trials Analysis
April 7, 2021updated 14 Apr 2021 4:50pm

UK accounts for 3.6% share of global clinical trial activity in 2020

The UK has accounted for a 3.6% share of the global clinical trials activity in 2020, registering a decrease when compared with the last ten-year average of a 6.1% share, according to GlobalData.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Industry sponsored trials outnumber non-industry sponsored trials in UK

Industry sponsored trials held an 84.6% share of all the clinical trials in the UK in 2020, when compared with the ten-year average of 80.8%. Non-industry sponsored trials accounted for a 15.4% share in 2020 as against the average of 19.2% in the last ten years.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Top therapy areas for industry sponsored clinical trials in UK

Oncology was the leading therapy area for industry sponsored clinical trials in the UK in 2020 with a 31.3% share, as against a five-year average of 31.0% and a ten-year average of 29.9%.

Infectious Disease held an 18.2% share in 2020, over a five-year average of 8.4% and a ten-year average of 9.5%.

Respiratory held a 10.7% share in 2020, compared to a five-year average of 8.1% and a ten-year average of 8.8%. Central Nervous System held a 9.8% share in 2020, as against a five-year average of 13.2% and a ten-year average of 12.9%.

Metabolic Disorders held a 6.4% share, over a five-year average of 6.8% and a ten-year average of 7.8%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Top therapy areas for non-industry sponsored clinical trials in UK

Infectious Disease was the leading therapy area for non-industry sponsored clinical trials in the UK in 2020 with a 35.5% share, as against a five-year average of 12.0% and a ten-year average of 12.7%.

Cardiovascular held a 14.5% share in 2020, over a five-year average of 15.5% and a ten-year average of 16.0%.

Central Nervous System held a 14.5% share in 2020, compared to a five-year average of 23.4% and a ten-year average of 20.6%. Respiratory held a 14.5% share in 2020, as against a five-year average of 8.5% and a ten-year average of 8.6%.

Oncology held a 12.1% share, over a five-year average of 13.1% and a ten-year average of 14.5%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Phase II trials lead industry sponsored clinical trials in UK in 2020

Phase II trials held a 38.7% share of industry sponsored clinical trials in the UK in 2020, over a five-year average of 37.5% and a ten-year average of 35.6%.

Phase III trials held a 38.4% share in 2020, as against a five-year average of 36.0% and a ten-year average of 35.7%. Phase I trials held a 17.3% share in 2020, compared to a five-year average of 18.7% and a ten-year average of 18.9%.

Phase IV trials held a 5.7% share in 2020, over a five-year average of 7.9% and a ten-year average of 9.9%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Phase II trials lead non-industry sponsored clinical trials in UK in 2020

Phase II trials held a 50.0% share of non-industry sponsored clinical trials in the UK in 2020, over a five-year average of 50.7% and a ten-year average of 45.3%.

Phase IV trials held a 22.6% share in 2020, as against a five-year average of 25.5% and a ten-year average of 29.9%. Phase III trials held a 21.0% share, compared to a five-year average of 16.3% and a ten-year average of 16.6%.

Phase I held a 6.5% share in 2020, over a five-year average of 7.5% and a ten-year average of 8.2%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Methodology:

The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena